Show simple item record

dc.contributor.authorClamp, Andrew R
dc.contributor.authorAdams, M
dc.contributor.authorAtkinson, Ronnie
dc.contributor.authorBoven, E
dc.contributor.authorCalvert, A Hilary
dc.contributor.authorCervantes, A
dc.contributor.authorGanesan, T S
dc.contributor.authorLotz, J
dc.contributor.authorVasey, P
dc.contributor.authorCheverton, P
dc.contributor.authorJayson, Gordon C
dc.date.accessioned2009-08-20T10:28:30Z
dc.date.available2009-08-20T10:28:30Z
dc.date.issued2004-10
dc.identifier.citationA phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer. 2004, 95 (1):114-9 Gynecol. Oncol.en
dc.identifier.issn0090-8258
dc.identifier.pmid15385119
dc.identifier.doi10.1016/j.ygyno.2004.06.047
dc.identifier.urihttp://hdl.handle.net/10541/77983
dc.description.abstractOBJECTIVES: There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1 mg/m(2) weekly for 3 weeks out of 4 (Arm B). RESULTS: There were no responses in the weekly arm and a radiological response rate of 5.3% (95% CI 0.3-21.8%) in the daily arm. Principal toxicities were myelosuppression and emesis. Grade 3/4 neutropenia occurred in 29% of patients in Arm A and 6% patients in Arm B. Seventy-one percent of patients in Arm A required red cell transfusions while on treatment. CONCLUSIONS: Exatecan is well tolerated in this poor prognosis group of patients but only has modest single agent activity when administered in a daily regimen.
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents, Phytogenic
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBridged Compounds
dc.subject.meshCamptothecin
dc.subject.meshDNA Topoisomerases, Type I
dc.subject.meshDrug Administration Schedule
dc.subject.meshDrug Resistance, Multiple
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshEnzyme Inhibitors
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshOvarian Neoplasms
dc.subject.meshTaxoids
dc.titleA phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Deparment of Medical Oncology, Christie Hospital, M20 4BX, UK.en
dc.identifier.journalGynecologic Oncologyen
html.description.abstractOBJECTIVES: There is an urgent need for new agents with activity in platinum- and taxane-resistant epithelial ovarian cancer. Exatecan mesylate is a novel topoisomerase I inhibitor with potent activity against ovarian cancer in vitro. A multicentre phase IIA study was conducted in patients with platinum- and taxane-resistant epithelial ovarian cancer. PATIENTS AND METHODS: Fifty-seven patients with bidimensionally measurable ovarian cancer, previously exposed to platinum and taxanes, whose disease had relapsed within 6 months of platinum-containing chemotherapy were randomised to one of two intravenous schedules of exatecan mesylate; 0.3 mg/m(2) daily for 5 days every 3 weeks (Arm A) or 2.1 mg/m(2) weekly for 3 weeks out of 4 (Arm B). RESULTS: There were no responses in the weekly arm and a radiological response rate of 5.3% (95% CI 0.3-21.8%) in the daily arm. Principal toxicities were myelosuppression and emesis. Grade 3/4 neutropenia occurred in 29% of patients in Arm A and 6% patients in Arm B. Seventy-one percent of patients in Arm A required red cell transfusions while on treatment. CONCLUSIONS: Exatecan is well tolerated in this poor prognosis group of patients but only has modest single agent activity when administered in a daily regimen.


Files in this item

This item appears in the following Collection(s)

Show simple item record